119 related articles for article (PubMed ID: 37030064)
1. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Li Y; Zhang J; Cai Y; Liu H; Yang W; Xu Y; Huang M
Biochem Biophys Res Commun; 2023 May; 658():107-115. PubMed ID: 37030064
[TBL] [Abstract][Full Text] [Related]
2. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
Liu H; Zhang Z; Zhen P; Zhou M
J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis.
Frisch SM; Schaller M; Cieply B
J Cell Sci; 2013 Jan; 126(Pt 1):21-9. PubMed ID: 23516327
[TBL] [Abstract][Full Text] [Related]
4. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.
Zou G; Ren B; Liu Y; Fu Y; Chen P; Li X; Luo S; He J; Gao G; Zeng Z; Xiong W; Li G; Huang Y; Xu K; Zhang W
Cancer Sci; 2018 Nov; 109(11):3416-3427. PubMed ID: 30151927
[TBL] [Abstract][Full Text] [Related]
5. The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.
Tan M; Asad M; Heong V; Wong MK; Tan TZ; Ye J; Kuay KT; Thiery JP; Scott C; Huang RY
Mol Oncol; 2019 Apr; 13(4):757-780. PubMed ID: 30548372
[TBL] [Abstract][Full Text] [Related]
6. Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/
Liu Y; Li W; Luo J; Wu Y; Xu Y; Chen T; Zhang W; Fu F
Dis Markers; 2021; 2021():3566749. PubMed ID: 34413913
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Cao L; Shao M; Schilder J; Guise T; Mohammad KS; Matei D
Oncogene; 2012 May; 31(20):2521-34. PubMed ID: 21963846
[TBL] [Abstract][Full Text] [Related]
8. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer.
Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L
Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864
[No Abstract] [Full Text] [Related]
9. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
Mak CS; Yung MM; Hui LM; Leung LL; Liang R; Chen K; Liu SS; Qin Y; Leung TH; Lee KF; Chan KK; Ngan HY; Chan DW
Mol Cancer; 2017 Jan; 16(1):11. PubMed ID: 28095864
[TBL] [Abstract][Full Text] [Related]
10. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
11. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
[TBL] [Abstract][Full Text] [Related]
12. MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
Chen Y; Wang DD; Wu YP; Su D; Zhou TY; Gai RH; Fu YY; Zheng L; He QJ; Zhu H; Yang B
Br J Cancer; 2017 Oct; 117(8):1192-1201. PubMed ID: 28817834
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
[TBL] [Abstract][Full Text] [Related]
14. The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer.
Mo J; Zhang L; Li H; Duan H; Wang D; Zhao X; Xie Y
J Ovarian Res; 2022 May; 15(1):61. PubMed ID: 35568893
[TBL] [Abstract][Full Text] [Related]
15. mir-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis.
Cheng X; Shen T; Liu P; Fang S; Yang Z; Li Y; Dong J
BMC Cancer; 2022 Nov; 22(1):1151. PubMed ID: 36348305
[TBL] [Abstract][Full Text] [Related]
16. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
Zhang S; Xiong H; Yang J; Yuan X
Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
[TBL] [Abstract][Full Text] [Related]
19. Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.
Yamanoi K; Matsumura N; Murphy SK; Baba T; Abiko K; Hamanishi J; Yamaguchi K; Koshiyama M; Konishi I; Mandai M
Oncotarget; 2016 Jul; 7(30):47620-47636. PubMed ID: 27323405
[TBL] [Abstract][Full Text] [Related]
20. The Overexpression of Keratin 23 Promotes Migration of Ovarian Cancer via Epithelial-Mesenchymal Transition.
Ren M; Gao Y; Chen Q; Zhao H; Zhao X; Yue W
Biomed Res Int; 2020; 2020():8218735. PubMed ID: 33204716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
